Biohacking Kompakt

Podcast episode 157 (in German)

News: Lipoprotein(a) – down 78 percent, and the heart does not notice

November 13, 2026

Our first news episode with four studies of the week. The biggest: pelacarsen lowered lipoprotein(a) by 78 percent in more than 8,000 heart patients, yet heart attacks and strokes were just as frequent.

What it is about

From now on, Paul and Paula look back on the week every Friday: new studies, what the scene is talking about and what is new on the site. At the centre is the Lp(a)HORIZON trial, published in full in the New England Journal of Medicine on November 7. Added to this are the weight-loss pill orforglipron for sleep apnea, a longevity powder with a dozen or so ingredients and a small omega-3 study, both with about six points lower blood pressure. From the scene: the interim tolerance of BPC-157 and other peptides in the US and magnesium as a sleep tip.

Key points

  • Lp(a)HORIZON (New England Journal of Medicine, November 7, 2026): 8,350 people who had already had a cardiovascular event and a lipoprotein(a) of at least 70 mg/dL received monthly pelacarsen or placebo for a median of 4.7 years. The level fell by 77.7 percent, major cardiovascular events occurred in 12.3 versus 12.1 percent, with no difference even at very high baseline levels.
  • Flu-like reactions to the injection occurred in 31.9 percent on pelacarsen and 5.8 percent on placebo, and 20.6 versus 7.5 percent stopped because of side effects. Novartis has discontinued the programme for this use.
  • The blood test remains useful: the level is largely genetically fixed and stable, so measuring once in a lifetime is enough. Anyone with a high level should be particularly consistent about LDL cholesterol, blood pressure and smoking. Three other drugs are still in large trials.
  • Orforglipron for sleep apnea (JAMA, November 9, 2026): in two trials with 363 and 349 people with marked overweight and on average more than 50 breathing pauses per hour, the number fell by 18 to 21 per hour after one year, on placebo by 4 to 5. Weight fell by 10 to 11 percent, systolic blood pressure by 7 to 8 mmHg.
  • A multi-component powder including glycine, alpha-ketoglutarate, fisetin and pterostilbene (European Heart Journal Open, November 4, 2026): in 61 randomised adults over 40, of whom 43 were analysed, systolic blood pressure after six months was 6.1 mmHg lower than in the control group, and the vessels were less stiff.
  • Omega-3 (Nutrients, November 9, 2026): in 100 people in Buenos Aires already taking blood pressure and cholesterol drugs, the daytime systolic value in 24-hour monitoring was 6.5 mmHg lower than on placebo after twelve weeks. Office measurements showed no reliable difference, and CRP did not change.

Chapters (episode in German)

  1. 0:00Premiere: the first news episode
  2. 0:38Lipoprotein(a) – and what the hedgehog has to do with it
  3. 1:53HORIZON: down 78 percent, just as many heart attacks
  4. 3:08Why that might be and why the test still matters
  5. 4:03Orforglipron for sleep apnea
  6. 5:29A longevity powder and the blood vessels
  7. 6:52Omega-3: six points in 24-hour monitoring
  8. 7:40From the scene: the peptide tolerance in the US
  9. 9:11Magnesium for sleep
  10. 9:49New on the site

Where the data stop

HORIZON applies to pelacarsen in people who had already had a heart attack, stroke or other vascular disease and were very well treated. Whether lowering earlier over decades or other drugs help is open. Pelacarsen and orforglipron are not approved in Germany; orforglipron has been approved in the US since April 2026.

For sleep apnea the pill does not replace the breathing mask: at around 30 pauses per hour one is still in the range of severe sleep apnea, and in the second trial the pill was added to the mask. The powder study is small and close to the manufacturer – one author works for the company, another received research funding from it – and nobody knows which ingredient works. The omega-3 study is a pilot study with many comparisons.

The interim tolerance of BPC-157 and five other peptides in US pharmacies is not an approval, nothing changes for Germany, and it has not changed the data. On magnesium for sleep, a review of 15 randomised trials arrives at a mixed picture.

Listen (in German)

Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music

Published on November 13, 2026.

The topic in the database

  • A genetically fixed blood lipid value that raises heart risk – with the full HORIZON figuresLipoprotein(a)

More episodes

All episodes in the app (German)

Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-11-15.